Brian Goldstein on Biotech Option Deals

View "Option Deals for Biotech: Ensuring They are Enforceable"

Brian Goldstein wrote “Option Deals for Biotech: Ensuring They are Enforceable” in Mergers & Acquisitions Law360, where he discusses the use of option deals by big pharma and early-stage biotech companies as a way of financing high-risk discovery, development and regulatory approvals, and the pros and cons of various option transactions.  This also appeared in the Life Sciences and Commercial Contracts sections of Law360.